STOCK TITAN

Praxis Precision Medicines Inc - PRAX STOCK NEWS

Welcome to our dedicated news page for Praxis Precision Medicines (Ticker: PRAX), a resource for investors and traders seeking the latest updates and insights on Praxis Precision Medicines.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Praxis Precision Medicines's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Praxis Precision Medicines's position in the market.

Rhea-AI Summary
Praxis Precision Medicines will host an R&D Day on October 2, reviewing progress in its pipeline programs, including the initiation of Phase 3 program for ulixacaltamide in essential tremor and advances in clinical epilepsy assets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.74%
Tags
conferences
-
Rhea-AI Summary
Praxis Precision Medicines to participate in fireside chat at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.11%
Tags
conferences
-
Rhea-AI Summary
Praxis Precision Medicines to present data from its clinical-stage epilepsy programs at the 35th International Epilepsy Congress. Phase 1 study of PRAX-628 shows a potentially best-in-class safety profile for focal epilepsy. PRAX-562 program shows broad anticonvulsant activity in multiple DEE mouse models. Positive impact on stock price expected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.76%
Tags
conferences
Rhea-AI Summary
Praxis Precision Medicines to present analyses from its Essential1 study of ulixacaltamide at MDS Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
conferences
-
Rhea-AI Summary
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) reported a corporate update and financial results, with $124.3 million cash as of June 30, 2023. The company is on track to initiate Phase 3 studies for ulixacaltamide in Q4 2023 after a favorable End-of-Phase 2 meeting with FDA. The PRAX-628 Phase 1 study showed consistent safety profile and target engagement in measures of qEEG activity at all doses with first administration. The company plans to hold an R&D Portfolio Day on October 2 to elaborate on their science and clinical progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
-
Rhea-AI Summary
Praxis Precision Medicines, Inc. (PRAX) announced positive data from the Essential1 study for ulixacaltamide, a potential therapy for Essential Tremor. Patients dosed with ulixacaltamide for up to 14 weeks showed maintained or improved efficacy results, while those withdrawing to placebo experienced worsening. The sub-study execution confirmed design features for the upcoming Phase 3 program expected to initiate in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.66%
Tags
none
Rhea-AI Summary
PRAX-628 Phase 1 study shows pharmacodynamic activity across all dose levels compared to placebo. PRAX-628 expected to be best-in-class treatment for focal epilepsy. Phase 2 PPR study results to be announced later this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.24%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
none
Rhea-AI Summary
Praxis Precision Medicines, Inc. announces the pricing of its public offering of common stock and pre-funded warrants
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.23%
Tags
Praxis Precision Medicines Inc

Nasdaq:PRAX

PRAX Rankings

PRAX Stock Data

942.57M
13.21M
0.17%
48.92%
3.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Boston

About PRAX

praxis precision medicines, inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. its lead product candidates include prax-114, an extrasynaptic-preferring gabaa receptor positive allosteric modulator that is in phase iia clinical trial for the treatment of major depressive disorder and perimenopausal depression; and prax-944, a selective small molecule inhibitor of t-type calcium channels, which is in phase iia clinical trial for the treatment of essential tremor. the company is also developing prax-562, a persistent sodium current blocker that is in phase i clinical trial to treat severe pediatric epilepsy and adult cephalgia; prax-222, an antisense oligonucleotide for patients with gain-of-function (gof) scn2a epilepsy; and kcnt1 program for the treatment of kcnt1 gof epilepsy. it has a cooperation and license agreement with rogcon inc.; a license agreement purdue neuroscience company; and a res